Butyrate stimulates the secretion of apolipoprotein B-100-containing lipoproteins from HepG2 cells by inhibiting the intracellular degradation. 1994

A Kaptein, and E C de Wit, and H M Princen
Gaubius Laboratory IVVO-TNO, Institute of Ageing and Vascular Research, Leiden, The Netherlands.

We have shown previously that sodium butyrate induces a 2-fold increase in the secretion of apo B-100 by HepG2 cells. The apo B-100 mRNA level was not changed in butyrate-treated cells, indicating regulation at the translational or co- or posttranslational level (Biochem. J. (1991) 278, 557-564). In this paper, the mechanism by which butyrate increases apo B-100 secretion was further investigated. Pulse-chase analysis showed that in control incubations only 18 +/- 4% of the total amount of labelled apo B-100, present intracellularly after a 10 min pulse period, was secreted after a 90 min chase period, indicating that the major part of newly synthesized apo B-100 is degraded intracellularly. After addition of butyrate the secreted amount increased to 32 +/- 6% of the total synthesized amount. Treatment of HepG2 cells with butyrate resulted in an enhanced intracellular concentration of triacylglycerols (+30%), with no or only a marginal effect on the cellular content of cholesterol and cholesteryl esters. Secretion of triacylglycerols (+90%) and cholesteryl esters (+78%), but not of cholesterol, was increased to the same extent as apo B-100 secretion (+102%). The total mass of triacylglycerols, i.e., the sum of triacylglycerols present intracellularly and secreted by HepG2 cells, was significantly increased upon incubation with butyrate (+32%), whereas the total mass of cholesteryl esters was not affected. Butyrate did not affect the buoyant density of apo B-100-containing lipoproteins secreted by HepG2 cells. These results suggest that an increased availability of triacylglycerols, formed after the addition of butyrate regulates the amount of apo B-100 degraded intracellularly and consequently apo B-100 secretion.

UI MeSH Term Description Entries
D002087 Butyrates Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. Butyrate,n-Butyrate,Butanoic Acids,Butyric Acids,Acids, Butanoic,Acids, Butyric,n Butyrate
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000418 Albumins Water-soluble proteins found in egg whites, blood, lymph, and other tissues and fluids. They coagulate upon heating. Albumin
D001055 Apolipoproteins B Major structural proteins of triacylglycerol-rich LIPOPROTEINS. There are two forms, apolipoprotein B-100 and apolipoprotein B-48, both derived from a single gene. ApoB-100 expressed in the liver is found in low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). ApoB-48 expressed in the intestine is found in CHYLOMICRONS. They are important in the biosynthesis, transport, and metabolism of triacylglycerol-rich lipoproteins. Plasma Apo-B levels are high in atherosclerotic patients but non-detectable in ABETALIPOPROTEINEMIA. Apo-B,Apo B,ApoB,Apoprotein (B),Apoproteins B
D016632 Apolipoprotein A-I The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE. Apo A-I,Apo A-1,Apo A-I Isoproteins,Apo A1,Apo AI,ApoA-1,ApoA-I,Apolipoprotein A-1,Apolipoprotein A-I Isoprotein-2,Apolipoprotein A-I Isoprotein-4,Apolipoprotein A-I Isoproteins,Apolipoprotein A1,Apolipoprotein AI,Apolipoprotein AI Propeptide,Pro-Apo A-I,Pro-Apolipoprotein A-I,Proapolipoprotein AI,Apo A I Isoproteins,Apolipoprotein A 1,Apolipoprotein A I,Apolipoprotein A I Isoprotein 2,Apolipoprotein A I Isoprotein 4,Apolipoprotein A I Isoproteins,Pro Apo A I,Pro Apolipoprotein A I
D053299 Apolipoprotein B-100 A 513-kDa protein synthesized in the LIVER. It serves as the major structural protein of low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). It is the ligand for the LDL receptor (RECEPTORS, LDL) that promotes cellular binding and internalization of LDL particles. Apo B-100,Apo-B-100,ApoB-100,Apo B 100,ApoB 100,Apolipoprotein B 100
D020148 Butyric Acid A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester. Butanoic Acid,Butyric Acid Magnesium Salt,Butyric Acid, Sodium Salt,Magnesium Butyrate,Magnesium Dibutyrate,Sodium Butyrate,Acid, Butanoic,Acid, Butyric,Butyrate, Magnesium,Butyrate, Sodium,Dibutyrate, Magnesium

Related Publications

A Kaptein, and E C de Wit, and H M Princen
May 2015, Biochimie,
A Kaptein, and E C de Wit, and H M Princen
February 1997, The Journal of biological chemistry,
A Kaptein, and E C de Wit, and H M Princen
January 2002, Molecular and cellular biochemistry,
A Kaptein, and E C de Wit, and H M Princen
March 1994, The Journal of biological chemistry,
A Kaptein, and E C de Wit, and H M Princen
March 1996, The Biochemical journal,
Copied contents to your clipboard!